Research Papers:

Resveratrol enhances polyubiquitination-mediated ARV7 degradation in prostate cancer cells

Sarah Wilson, Lucia Cavero, Dali Tong, Qiuli Liu, Kyla Geary, Nicholas Talamonti, Jing Xu, Junjiang Fu, Jun Jiang _ and Dianzheng Zhang

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2017; 8:54683-54693. https://doi.org/10.18632/oncotarget.18003

Metrics: PDF 2455 views  |   HTML 3076 views  |   ?  


Sarah Wilson1,2,*, Lucia Cavero1,2,*, Dali Tong3, Qiuli Liu3, Kyla Geary1,2, Nicholas Talamonti1,2, Jing Xu3, Junjiang Fu4, Jun Jiang3 and Dianzheng Zhang1,2

1Department of Bio-Medical Sciences, Philadelphia College of Osteopathic Medicine, Philadelphia, Pennsylvania 19131, USA

2Center for Chronic Disorders of Aging, Philadelphia College of Osteopathic Medicine, Philadelphia, Pennsylvania 19131, USA

3Department of Urology, Institute of Surgery Research, Daping Hospital, Third Military Medical University, Chongqing 400042, China

4Key Laboratory of Epigenetics and Oncology, The Research Center for Preclinical Medicine, Southwest Medical University, Luzhou, Sichuan 646000, China

*These authors contributed equally to this work

Correspondence to:

Jun Jiang, email: [email protected]

Dianzheng Zhang, email: [email protected]

Keywords: prostate cancer, ARV7, resveratrol, polyubiquitination, castration resistance

Received: December 21, 2016     Accepted: May 08, 2017     Published: May 19, 2017


Although androgen deprivation therapy (ADT) serves as the primary treatment option for localized or metastatic prostate cancer, most cases eventually develop into castration-resistant prostate cancer (CRPC). However, androgen receptor (AR) continues to be functional in CRPC through various mechanisms, including the development of AR splicing variants, especially ARV7. Since it lacks the ligand binding domain but retains the intact DNA binding domain, ARV7 is constitutively active, which makes ARV7-positive prostate cancer responsive to neither abiraterone nor enzalutamide. In this study, we explored the effect of resveratrol on ARV7 transcriptional activity and the potential for development of resveratrol as a treatment for ARV7-positive prostate cancer. First, we ectopically expressed ARV7 in PC3 cells, an AR-negative prostate cancer cell line, and demonstrated that resveratrol is capable of inhibiting ARV7 transcriptional activity by downregulating ARV7 protein levels. Of note, resveratrol does not affect the mRNA levels of ARV7 nor its nuclear translocation. Next, we demonstrated that resveratrol is capable of downregulating the levels of the endogenously expressed ARV7 as well as AR target gene mRNAs in 22RV1 prostate cancer cells. Mechanistically, resveratrol downregulates ARV7 by enhancing ARV7 polyubiquitination and subsequent proteasome-mediated degradation. These findings suggest that resveratrol could be a potential treatment for ARV7-positive CPRC.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 18003